stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Return on assets
Arcus Biosciences, Inc.'s return on assets over the twelve months to 30 September 2026 was −50.6%, down 19.7 percentage points from fiscal 2025 (−30.8%). Over the past ten years it has ranged from −55.7% (fiscal 2017) to 4.48% (fiscal 2021); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −30.8% | (5.63) |
| FY2024 | −25.2% | (0.05) |
| FY2023 | −25.2% | (6.98) |
| FY2022 | −18.2% | (22.66) |
| FY2021 | 4.48% | 29.70 |
| FY2020 | −25.2% | 10.22 |
| FY2019 | −35.4% | (14.13) |
| FY2018 | −21.3% | 34.42 |
| FY2017 | −55.7% | (36.81) |
| FY2016 | −18.9% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| BEAM Beam Therapeutics Inc. compare | −8.40% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −18.2% |
| XNCR Xencor, Inc. compare | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| MBX MBX Biosciences, Inc. compare | −31.3% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| RCUS Arcus Biosciences, Inc. | −50.6% |
| PHVS Pharvaris N.V. compare | −64.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement